Novel and emerging therapies for asthma

Drug Discovery Today

Volumn 10, Issue 23-24, 2005, Pages 1647-1655

  Leath, Thomas M ^a   Singla, Manav ^a   Peters, Stephen P ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BECLOBRATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CILOMILAST; CORTICOSTEROID; GAMMA INTERFERON; IMATINIB; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 4 ANTIBODY; INTERLEUKIN 5 ANTIBODY; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OLIGODEOXYNUCLEOTIDE DERIVATIVE; OMALIZUMAB; PHOSPHODIESTERASE IV INHIBITOR; PROSTANOID RECEPTOR; ROFLUMILAST; SELECTIN; SERATRODAST; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE A2; THROMBOXANE SYNTHASE INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY; VERY LATE ACTIVATION ANTIGEN 4;

ALLERGIC ASTHMA; ANGIOGENESIS; CPG ISLAND; CYTOKINE PRODUCTION; DRUG SELECTIVITY; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; HUMAN; IMMUNOMODULATION; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CPG ISLANDS; CYTOKINES; HUMANS; IMMUNOGLOBULIN E; LEUKOTRIENE ANTAGONISTS; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGODEOXYRIBONUCLEOTIDES; PHOSPHODIESTERASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 29144471028     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03646-9     Document Type: Review

References (104)

1. D.P. Spence The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma Am. J. Respir. Crit. Care Med. 149 1994 1142 1148
2. L.M. Kuitert Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma Am. J. Respir. Crit. Care Med. 151 1995 1331 1335
3. J.M. Drazen Treatment of asthma with drugs modifying the leukotriene pathway N. Engl. J. Med. 340 1999 197 206
4. R.J. Horwitz The role of leukotriene modifiers in the treatment of asthma Am. J. Respir. Crit. Care Med. 157 1998 1363 1371
5. P.M. O'Byrne Antileukotrienes in the treatment of asthma Ann. Intern. Med. 127 1997 472 480
6. H.G. Morris Radioimmunoassay of thromboxane B2 in plasma of normal and asthmatic subjects Adv. Prostaglandin Thromboxane Res. 8 1980 1759 1764
7. R. Greenberg Thromboxane A2 mediated bronchoconstriction in the anesthetized guinea pig Eur. J. Pharmacol. 80 1982 19 27
8. J. Svenssen Thromboxane A2: effects on airway and vascular smooth muscle Prostaglandins 14 1977 425 436
9. Y. Ashida A novel anti-asthmatic quinone derivative, AA-2414 with a potent antagonistic activity against a variety of spasmogenic prostanoids Prostaglandins 38 1989 91 112
10. M. Fujimura Effect of a thromboxane A2 receptor antagonist (AA-2414) on bronchial hyperresponsiveness to methacholine in subjects with asthma J. Allergy Clin. Immunol. 87 1991 23 27
11. T. Fukuoka The effect of seratrodast on eosinophil cationic protein and symptoms in asthmatics J. Asthma 40 2003 257 264
12. M. Hoshino Effect of AA-2414, a thromboxane A2 receptor antagonist, on airway inflammation in subjects with asthma J. Allergy Clin. Immunol. 103 1999 1054 1061
13. J. Tamaoki Effect of a thromboxane A(2) antagonist on sputum production and its physicochemical properties in patients with mild to moderate asthma Chest 118 2000 73 79
14. C.C. Hardy The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men N. Engl. J. Med. 311 1984 209 213
15. M.A. Wasserman Bronchopulmonary and cardiovascular effects of prostaglandin D2 in the dog Prostaglandins 13 1977 255 269
16. T. Matsuoka Prostaglandin D2 as a mediator of allergic asthma Science 287 2000 2013 2017
17. S. Mitsumori Synthesis and biological activity of various derivatives of a novel class of potent, selective, and orally active prostaglandin D2 receptor antagonists. 2. 6,6-Dimethylbicyclo[3.1.1]heptane derivatives J. Med. Chem. 46 2003 2446 2455
18. S. Mitsumori Synthesis and biological activity of various derivatives of a novel class of potent, selective, and orally active prostaglandin D2 receptor antagonists. 1. Bicyclo[2.2.1]heptane derivatives J. Med. Chem. 46 2003 2436 2445
19. K. Torisu Development of prostaglandin D2 receptor antagonist: discovery of highly potent antagonists Bioorg. Med. Chem. 12 2004 4685 4700
20. T. Ishizuka Ramatroban (BAY u 3405): a novel dual antagonist of TXA2 receptor and CRTh2, a newly identified prostaglandin D2 receptor Cardiovasc. Drug Rev. 22 2004 71 90
21. H. Magnussen Effects of a thromboxane-receptor antagonist, BAY u 3405, on prostaglandin D2- and exercise-induced bronchoconstriction J. Allergy Clin. Immunol. 89 1992 1119 1126
22. H. Aizawa BAY u3405, a thromboxane A2 antagonist, reduces bronchial hyperresponsiveness in asthmatics Chest 109 1996 338 342
23. D. Spina Theophylline and PDE4 inhibitors in asthma Curr. Opin. Pulm. Med. 9 2003 57 65
24. B.J. Lipworth Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease Lancet 365 2005 167 175
25. H.A. Boushey, J.V. Fahy Targeting cytokines in asthma therapy: round one Lancet 356 2000 2114 2116
26. P.J. Barnes New directions in allergic diseases: mechanism-based anti-inflammatory therapies J. Allergy Clin. Immunol. 106 2000 5 16
27. A.M. Colavita Contributing factors to the pathobiology of asthma. The Th1/Th2 paradigm Clin. Chest Med. 21 2000 263 277
28. L.C. Borish Interleukin-4 receptor in moderate atopic asthma. A Phase I/II randomized, placebo-controlled trial Am. J. Respir. Crit. Care Med. 160 1999 1816 1823
29. L.C. Borish Efficacy of soluble IL-4 receptor for the treatment of adults with asthma J. Allergy Clin. Immunol. 107 2001 963 970
30. M. Wills-Karp Interleukin-13 in asthma pathogenesis Immunol. Rev. 202 2004 175 190
31. G. Yang Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice J. Pharmacol. Exp. Ther. 313 2005 8 15
32. M.J. Leckie Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response Lancet 356 2000 2144 2148
33. J.C. Kips Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study Am. J. Respir. Crit. Care Med. 167 2003 1655 1659
34. P.T. Flood-Page Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway Am. J. Respir. Crit. Care Med. 167 2003 199 204
35. P.M. O'Byrne Reassessing the Th2 cytokine basis of asthma Trends Pharmacol. Sci. 25 2004 244 248
36. S.A. Bryan Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response Lancet 356 2000 2149 2153
37. W.W. Busse, L.J. Rosenwasser Mechanisms of asthma J. Allergy Clin. Immunol 111 2003 S799 S804
38. L.C. Borish, J.W. Steinke 2. Cytokines and chemokines J. Allergy Clin. Immunol. 111 2003 460 475
39. H.U. Simon Clinical and immunological effects of low-dose IFN-alpha treatment in patients with corticosteroid-resistant asthma Allergy 58 2003 1250 1255
40. M. Boguniewicz Treatment of steroid-dependent asthma with recombinant interferon-gamma Clin. Exp. Allergy 23 1993 785 790
41. M. Boguniewicz The effects of nebulized recombinant interferon-[gamma] in asthmatic airways J. Allergy Clin. Immunol. 95 1995 133 135
42. K.S. Babu Role of tumor necrosis factor alpha in asthma Immunol. Allergy Clin. North Am. 24 2004 583 597
43. J. Xu, N.S. Zhong The interaction of tumour necrosis factor alpha and endothelin-1 in pathogenetic models of asthma Clin. Exp. Allergy 27 1997 568 573
44. P.S. Thomas, G. Heywood Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma Thorax 57 2002 774 778
45. S. Wenzel Mechanisms of severe asthma Clin. Exp. Allergy 33 2003 1622 1628
46. C. Khalil Saadeh Infliximab therapy for rheumatoid arthritis (RA) induced significant control of asthma in patients with both RA and asthma or asthma/COPD in addition to improving RA status Journal of Allergy and Clinical Immunology 109 2002 S243 (Abstract 741)
47. K.S. Babu, S.H. Arshad Soluble tumor necrosis factor alpha (TNF-alpha) receptor as an effective theraputic strategy in chronic severe asthma Journal of Allergy and Clinical Immunology 111 2003 S277 (Abstract 838)
48. N. Oda Effect of suplatast tosilate (IPD-1151T) on cytokine production by allergen-specific human Th1 and Th2 cell lines Life Sci. 65 1999 763 770
49. A. Koda IPD-1151T: a prototype drug for IgE antibody synthesis modulation Agents Actions Suppl. 34 1991 369 378
50. J. Tamaoki Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study. Tokyo Joshi-Idai Asthma Research Group Lancet 356 2000 273 278
51. T. Sano Add-on effects of suplatast tosilate in bronchial asthma patients treated with inhaled corticosteroids Lung 181 2003 227 235
52. N.W. Lukacs Chemokine receptors in asthma: searching for the correct immune targets J. Immunol. 171 2003 11 15
53. U. Forssmann n-Nonanoyl-CC chemokine ligand 14, a potent CC chemokine ligand 14 analogue that prevents the recruitment of eosinophils in allergic airway inflammation J. Immunol. 173 2004 3456 3466
54. S. Hatse Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4 FEBS Lett. 527 2002 255 262
55. N.W. Lukacs AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity Am. J. Pathol. 160 2002 1353 1360
56. B.S. Bochner Adhesion molecules as therapeutic targets Immunol. Allergy Clin. North Am. 24 2004 615 630
57. E. Kudlacz Pulmonary eosinophilia in a murine model of allergic inflammation is attenuated by small molecule alpha4beta1 antagonists J. Pharmacol. Exp. Ther. 301 2002 747 752
58. M.T. Borchers Blockade of CD49d inhibits allergic airway pathologies independent of effects on leukocyte recruitment Am. J. Physiol. Lung Cell. Mol. Physiol 280 2001 L813 L821
59. A. Kanehiro Timing of administration of anti-VLA-4 differentiates airway hyperresponsiveness in the central and peripheral airways in mice Am. J. Respir. Crit. Care Med. 162 2000 1132 1139
60. G.M. Gauvreau The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma J. Allergy Clin. Immunol. 112 2003 331 338
61. P.C. Avila Effect of a single dose of the selectin inhibitor TBC1269 on early and late asthmatic responses Clin. Exp. Allergy 34 2004 77 84
62. W.W. Busse, R.F. Lemanske Jr Asthma N. Engl. J. Med. 344 2001 350 362
63. C.G. Lee Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung Nat. Med. 10 2004 1095 1103
64. M.E. Rothenberg VEGF obstructs the lungs Nat. Med. 10 2004 1041 1042
65. R.M. Tuder Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade Am. J. Respir. Cell Mol. Biol. 29 2003 88 97
66. Y. Kasahara Inhibition of VEGF receptors causes lung cell apoptosis and emphysema J. Clin. Invest. 106 2000 1311 1319
67. D.M. Ross, T.P. Hughes Cancer treatment with kinase inhibitors: what have we learnt from imatinib? Br J. Cancer 90 2004 12 19
68. G. Marcucci Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed, et al. (2003) The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations Clin. Cancer Res. 9 2003 1333 1337 Clin. Cancer Res. 9. 1248-1252
69. P. Trempat Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571/Glivec Oncogene 22 2003 5702 5706
70. A. Levitzki PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases Cytokine Growth Factor Rev. 15 2004 229 235
71. M.C. Heinrich Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor Blood 96 2000 925 932
72. G.D. Demetri Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N. Engl. J. Med. 347 2002 472 480
73. P.G. Casali Imatinib mesylate in chordoma Cancer 101 2004 2086 2097
74. A.A. Berlin, N.W. Lukacs Treatment of cockroach allergen asthma model with imatinib attenuates airway responses Am. J. Respir. Crit. Care Med. 171 2005 35 39
75. J. Cools A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome N. Engl. J. Med. 348 2003 1201 1214
76. J.E. Darnell Jr Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins Science 264 1994 1415 1421
77. C.W. Schindler Series introduction. JAK-STAT signaling in human disease J. Clin. Invest. 109 2002 1133 1137
78. I.M. Wang STAT-1 is activated by IL-4 and IL-13 in multiple cell types Mol. Immunol. 41 2004 873 884
79. D. Quarcoo Inhibition of signal transducer and activator of transcription 1 attenuates allergen-induced airway inflammation and hyperreactivity J. Allergy Clin. Immunol. 114 2004 288 295
80. L. Borish Genetics of allergy and asthma Ann. Allergy Asthma Immunol. 82 1999 413 424
81. A.B. Pernis, P.B. Rothman JAK-STAT signaling in asthma J. Clin. Invest. 109 2002 1279 1283
82. S. Weidinger Association of a STAT 6 haplotype with elevated serum IgE levels in a population based cohort of white adults J. Med. Genet. 41 2004 658 663
83. C. Desmet Treatment of experimental asthma by decoy- mediated local inhibition of activator protein-1 Am. J. Respir. Crit. Care Med. 172 2005 671 678
84. C. Desmet Selective blockade of NF-kB activity in airway immune cells inhibits the effector phase of experimental asthma J. Immunol. 173 2004 5766 5775
85. K. El Bakkouri Adenoviral gene transfer of the NF-kB inhibitory protein ABIN-1 decreases allergic airway inflammation in a murine asthma model J. Biol. Chem. 280 2005 17938 17944
86. L.A. Hart Activation and localization of transcription factor, nuclear factor-kappaB, in asthma Am. J. Respir. Crit. Care Med. 158 1998 1585 1592
87. W. Busse Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma J. Allergy Clin. Immunol. 108 2001 184 190
88. M. Soler The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Eur. Respir. J. 18 2001 254 261
89. S.T. Holgate Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma Clin. Exp. Allergy 34 2004 632 638
90. M. Humbert Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE Allergy 60 2005 309 316
91. J. Bousquet Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma Chest 125 2004 1378 1386
92. R. Djukanovic Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma Am. J. Respir. Crit. Care Med. 170 2004 583 593
93. J. Corren Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma J. Allergy Clin. Immunol. 111 2003 87 90
94. H. Milgrom Treatment of childhood asthma with anti-immunoglobulin E antibody (Omalizumab) Pediatrics 108 2001 e36
95. A.M. Vignola Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR Allergy 59 2004 709 717
96. V.V. Jain CpG DNA and immunotherapy of allergic airway diseases Clin. Exp. Allergy 33 2003 1330 1335
97. P.S. Norman Immunotherapy: 1999-2004 J. Allergy Clin. Immunol. 113 2004 1013 1023
98. D.K. Agrawal Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma Int. Immunopharmacol. 4 2004 127 138
99. J.N. Kline CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma J. Allergy Clin. Immunol. 104 1999 1258 1264
100. J.N. Kline Treatment of established asthma in a murine model using CpG oligodeoxynucleotides Am. J. Physiol. Lung Cell. Mol. Physiol 283 2002 L170 L179
101. V.V. Jain CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma J. Allergy Clin. Immunol. 110 2002 867 872
102. H.L. Spiegelberg Allergen-immunostimulatory oligodeoxynucleotide conjugate: a novel allergoid for immunotherapy Curr. Opin. Allergy Clin. Immunol. 2 2002 547 551
103. M.K. Tulic Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response J. Allergy Clin. Immunol. 113 2004 235 241
104. F.E. Simons Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA J. Allergy Clin. Immunol. 113 2004 1144 1151